Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment

被引：0
|
作者：
Saleh, Soundos
Becker, Corina
Frey, Reiner
Mueck, Wolfgang
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2014年 / 44卷
关键词：
Pulmonary hypertension;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P2354
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment
    Saleh, Soundos
    Becker, Corina
    Frey, Reiner
    Mueck, Wolfgang
    PULMONARY CIRCULATION, 2016, 6 : S75 - S85
  • [2] Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).
    Sarantopoulos, John
    Mita, Alain C.
    He, Aiwu Ruth
    Wade, James Lloyd
    Hsueh, Chung-Tsen
    Morris, John Charles
    Lockhart, Albert C.
    Quinn, David
    Hwang, Jimmy J.
    Mier, James Walter
    Zhang, Wenping
    Wack, Claudine
    Yin, Jian
    Clot, Pierre-Francois
    Rixe, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma
    Kang, D.
    Wang, E.
    Wang, D.
    Amantea, M.
    Hsyu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Pharmacokinetics (PK) of tigecycline (TGC) in patients with hepatic impairment
    Böhmer, GM
    Baird-Bellaire, S
    Patat, A
    Gleiter, CH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 703 - 703
  • [5] Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
    Marbury, Thomas
    Dowell, James A.
    Seltzer, Elyse
    Buckwalter, Mary
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (04): : 465 - 476
  • [6] Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
    Preston, Richard A.
    Marbury, Thomas
    Balaratnam, Ganesh
    Green, Michelle
    Dixon, Sandy
    Lehrer-Graiwer, Josh
    Washington, Carla
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (04): : 493 - 505
  • [7] THE ROLE OF POPULATION PK IN INFORMING DOSING RECOMMENDATIONS FOR PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT.
    Younis, I. R.
    Sinha, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S103 - S103
  • [8] Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
    deZeeuw, D
    Remuzzi, G
    Kirch, W
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S37 - S42
  • [9] Pharmacokinetics Of The Soluble Guanylate Cyclase Stimulator Riociguat In Individuals With Hepatic Impairment
    Frey, R.
    Becker, C.
    Unger, S.
    Schmidt, A.
    Wensing, G.
    Mueck, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [10] Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
    Reiner Frey
    Corina Becker
    Sigrun Unger
    Anja Schmidt
    Georg Wensing
    Wolfgang Mueck
    BMC Pharmacology and Toxicology, 14 (Suppl 1)
12345